You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



FOB & PW Update – CRS Part II

Overview of qualification criteria of Reporting Financial Institutions under the Automatic Exchange of Information and the Common Reporting Standard. read more
Cellularline deal notice

Loyens & Loeff advised Cellularline S.p.A.

Loyens & Loeff advised Cellularline S.p.A. on the acquisition of 80% of the shares in WorldConnect AG against a consideration of CHF 15.8 million. read more
Chambers and Partners Europe 2020 - Loyens & Loeff Belgium

Loyens & Loeff recognised as Top-tier Law Firm

Today, 9 July 2020, Chambers & Partners High Net Worth (HNW) has published its rankings for 2020. read more